020413 -- International Stem Cell Corporation (OTCQB: ISCO) br (www.internationalstemcell.com) (ISCO or the Company) a California-based biotechnology br company, today announced positive 12-week results from its pre-clinical in vivo br Parkinson's disease study. The primary goal of this behavioral study was to demonstrate br the therapeutic benefits of neuronal cells derived from human parthenogenetic stem cell br (hpSC) line in a rat model of Parkinson's disease (PD).